WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on the health and safety of people and their environment, today announced that its ViaCord Research Institute™ (VRI™), which focuses on supporting science, technology and medical treatments using cord blood stem cells, will support the University of Massachusetts Medical School (UMMS) in its research efforts into the potential use of umbilical cord blood-derived stem cells in treating type 1 diabetes. The initiative will be led by chief investigator Dale L. Greiner, Ph.D., of UMMS’ Diabetes and Endocrinology Research Center.
